Antibacterial Agents TRIZ Cases

Reducing antigen and adjuvant in the second administration minimizes reactogenicity while sustaining long-lasting immunity.

Hydrophobic modified penetratin derivatives overcome ocular barriers to boost drug absorption without causing irritation or toxicity.

Dencichine preparations treat thrombocytopenia by increasing platelet counts and improving aggregation without blood-borne infection risks.

Pegylated interleukin-10 conjugates extend serum half-life, maintaining stable trough concentrations to improve solid tumor treatment efficacy.

A fusion protein with an N-terminal APC-binding domain delivers antigens to immune cells.

Segmented subunit vaccines induce systemic and local immunity while eliminating adverse reactions from virulent strains.

N-(4-oxo-4H-thieno[3,4-c]chromen-3-yl)-3-phenylprop-2-ynamide binds to HlyU to inhibit RTX toxin production.

Formaldehyde-treated recombinant toxins reduce pathogenic toxicity while preserving immunogenic epitopes to prevent recurrent infection.

A pyrrole sulfonyl derivative acts as a potassium-competitive acid blocker to inhibit gastric secretion.

Cationic intrinsically disordered antimicrobial peptides overcome antibiotic resistance while maintaining low cytotoxicity and synthesis costs.

Combining fluoroquinolones with antiviral or antifungal agents treats mixed pathogen infections immediately, overcoming antibiotic resistance delays.

Antibodies bind protective antigen to block cellular receptor attachment and prevent toxin oligomerization.

Single-dose vaccine merges protein antigen, DNA plasmid, and QS21 adjuvant to stimulate CD4+ and CD8+ T-cell responses without prime-boost schedules.

Azasteroid compounds combined with anti-tuberculosis drugs shorten treatment duration and reduce toxicity while addressing drug-resistant strains.

Segmented gastric residence systems with pH-responsive linkers maintain stomach stability while preventing intestinal obstruction from premature passage.

A pharmaceutical composition combining clofazimine, ethambutol, pyrazinamide, and prothionamide or bedaquiline for tuberculosis treatment.

Michelicin peptides employ BRICHOS domains to eliminate bacterial resistance while preventing human cell cytotoxicity.

Polymeric biguanide and vicinal diol composition eliminates chronic wound biofilms within ten minutes, preventing regrowth and accelerating healing.

Pre-assembled sulfonamide-amino building blocks enable rapid peptide coupling on molecular arrays.

CbpA fusion protein intercepts pneumococcal attachment to prevent cardiac microlesions and adverse events.

Simultaneous administration of rifaximin and antibiotic-resistant Bifidobacterium longum W11 maintains intestinal flora balance during infection treatment.

Lactobacillus plantarum and Bifidobacterium strains resolve the contradiction between pathogen inhibition and gut balance, avoiding surgical risks.

Segmented antigens resolve vaccinated animal interference, enabling accurate infection detection.

Sirolimus and tetracyclines halt disease progression by blocking prion transcription and amyloid synthesis.

Nonionic surfactants solubilize fluocinolone acetonide in a preservative-free aqueous solution, eliminating organic solvent irritation.

Copolymer coatings link drugs via oligomeric segments to prevent phase separation and maintain mechanical integrity during release.

Thiazole compounds inhibit metallo-beta-lactamase enzymes, restoring beta-lactam antibiotic efficacy against resistant bacterial infections.

A multi-strain probiotic feed additive stimulates chicken immune function and enhances growth performance.

Thymidine auxotrophy and suppressor tRNA replace antibiotic markers, eliminating contamination risks while maintaining high-yield plasmid production.

Skin-applied dry antigen eliminates adjuvant need while orienting immune response toward TH1 pathways.

Benzaldehyde derivatives combined with cinnamic or anisic acid provide broad-spectrum antimicrobial activity in personal care formulations.

Composite pentameric secretory IgM resists gastrointestinal degradation, reducing relapse rates and minimizing intestinal flora disruption.

Engineered antibodies binding ICAM-1 induce apoptosis in cancer cells while sparing normal tissue.

Polyvinylpyrrolidone stabilizes percarboxylic acid, preventing decomposition and enabling safe skin application.

Targeting platelet IP6K1 enhances bacterial killing while minimizing inflammation-induced tissue damage during pneumonia treatment.

Multivalent cholera MEFA fusion antigens combine consensus backbone sequences with heterologous Vibrio cholerae epitopes to induce broad immunogenic responses.

Lipophilic group integration enables traversal of Gram-negative outer membranes while reducing cytotoxicity against multidrug-resistant pathogens.

High-affinity EphB3 antagonists inhibit receptor activity, addressing therapeutic complexity through preliminary antibody characterization.

Specific molecular structure overcomes pest resistance while maintaining low toxicity for non-target organisms.

Sol-gel precursors form a stable metal oxide shell around a phase changing material core to prevent leakage of active agents.